Treat Obesity First
We view obesity as a chronic disease and believe that treating it first is a priority to supporting broader, long-term benefits and a healthier life.
At the center of our pipeline is VK2735, a dual GLP-1/GIP receptor agonist with the potential to be the first dual agonist available in both oral and injectable formulations. VK2735 has demonstrated compelling efficacy in clinical trials and is now in Phase 3 obesity studies. With its unique dosing and administration options, it may offer flexible treatment from initial weight loss to ongoing management designed to support patients in improving overall health.
Beyond VK2735, Viking is advancing additional programs targeting metabolic and liver diseases, including VK2809, as well as next-generation approaches for obesity, such as amylin-based therapies.
